Clinical trials: sponsored by Dana-Farber Cancer Institute
Renal Carcinoma, Renal Cell Carcinoma
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood…
- Conditions
- Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT06318871
- Testing
- Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2)
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Primary Central Nervous System Lymphoma
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects.
- Trial name
- NCT06475235
- Testing
- Pembrolizumab, Methotrexate, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
This research study is evaluating a new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02158091
- Testing
- IPI-145, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: Venetoclax Daunorubicin Cytarabine
- Trial name
- NCT03709758
- Testing
- Venetoclax, Daunorubicin, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Small Cell Lung Cancer
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
- Trial name
- NCT03122717
- Testing
- Gefitinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung
Osimertinib In EGFR Mutant Lung Cancer
This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: Osimertinib (Tagrisso)
- Trial name
- NCT03586453
- Testing
- Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Primary Central Nervous System Lymphoma, Recurrent Cancer
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).
- Conditions
- Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
- Trial name
- NCT04421560
- Testing
- Ibrutinib, Pembrolizumab, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
- Conditions
- Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
- Trial name
- I-MAC (NCT06805617)
- Testing
- Ivonescimab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
- Conditions
- Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)
- Trial name
- NCT04416568
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer
INHERIT EGFR - Studying Germline EGFR Mutations
Lung cancer is a common malignancy that is associated with cigarette smoking but can also affect individuals who never smoked. It is not well understood whether there are hereditary risk factors that influence the risk of lung…
- Trial name
- INHERIT (NCT01754025)
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- Dana-Farber Cancer Institute
Genetic Testing, Breast Cancer
Video Education With Result Dependent dIsclosure
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic…
- Conditions
- Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- VERDI (NCT05225428)
- Testing
- Video Education, Genetic Counseling
- Where
- United States
- Volunteers
- 1,334 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
- Trial name
- NCT05265429
- Testing
- Data and Specimen Collection
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody)…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- NCT06239220
- Testing
- PD-L1 t-haNK, Cetuximab, NAI
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery.
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
- Trial name
- NCT06664151
- Testing
- Fluzone Trivalent
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Recurrent Endometrial Cancer
ALPINE: Maintenance Letrozole/Abemaciclib
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53)…
- Conditions
- Endometrial Cancer, Recurrent Endometrial Cancer, TP53
- Trial name
- NCT06366347
- Testing
- Abemaciclib, Letrozole, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer
Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention
This trial will evaluate the SHARE-MC educational intervention designed to address sexual health needs and related adjustment in women with metastatic breast cancer.
- Trial name
- SHARE-MC (NCT07519200)
- Testing
- SHARE-MC, Informational Booklet
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkin's Lymphoma, Hodgkin's Disease
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different…
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders
- Trial name
- NCT00131014
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
Understanding Chronic Lymphocytic Leukemia
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
- Trial name
- NCT04028531
- Where
- United States
- Volunteers
- 2,750 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cancer, Pain
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
- Trial name
- NCT06117709
- Testing
- I-STAMP
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Dana-Farber Cancer Institute